Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human lesion studies

V Fuster1

  • 1Cardiovascular Institute, Mount Sinai Medical Center, New York, New York 10029-6574, USA.

Annals of the New York Academy of Sciences
|April 15, 1997
PubMed
Summary
This summary is machine-generated.

Lipid-lowering therapy stabilizes vulnerable plaques and prevents acute coronary syndromes (ACS) by reducing lipid content and macrophage activity. This improves plaque stability and secondary prevention in cardiovascular disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Widowhood, illegitimacy, marital reproduction and female longevity in a rural Spanish population.

Homo : internationale Zeitschrift fur die vergleichende Forschung am Menschen·2011
Same author

From treating complex coronary artery disease to promoting cardiovascular health: therapeutic transitions and challenges, 2010-2020.

Clinical pharmacology and therapeutics·2011
Same author

Hirudin and other thrombin inhibitors experimental results and potential clinical applications.

Trends in cardiovascular medicine·2011
Same author

Doubts about ventricular reconstruction.

Nature reviews. Cardiology·2009
Same author

[Cardiovascular disease and chronic kidney disease: from treatment to promoting health].

Medicina clinica·2009
Same author

[Cardiovascular, renal and other chronic diseases. Early intervention is necessary in chronic kidney disease].

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia·2009
Same journal

Global Trends in Light Pollution and Their Relationship With Socioeconomic Factors.

Annals of the New York Academy of Sciences·2026
Same journal

Wired for Corruption: Inter-Brain Synchrony Encodes Bribery-Related Value Information and Predicts Bribery Agreement.

Annals of the New York Academy of Sciences·2026
Same journal

LM-YOLO: A Lightweight Multi-Scale Enhanced Model for Forest Smoke Detection Using Unmanned Aerial Vehicles.

Annals of the New York Academy of Sciences·2026
Same journal

Polyrhythm Perception and Production: A Scoping Review.

Annals of the New York Academy of Sciences·2026
Same journal

DARTS-CNN-BiLSTM: Intelligent Fault Diagnosis for Computer Numerical Control Machine Tool Feed System.

Annals of the New York Academy of Sciences·2026
Same journal

Synchrony and Reciprocity in Rhythmic Interaction.

Annals of the New York Academy of Sciences·2026
See all related articles

Area of Science:

  • Cardiovascular Medicine
  • Atherosclerosis Research
  • Lipid Metabolism

Background:

  • Atherothrombotic processes underlie acute coronary syndromes (ACS).
  • Coronary atherosclerosis progresses through defined lesion types (I-VI).
  • Vulnerable plaques, characterized by high lipid content, are prone to disruption and thrombosis.

Purpose of the Study:

  • To review recent information on atherothrombotic processes in ACS.
  • To outline the impact of lipid-lowering therapy on plaque stabilization and secondary prevention.
  • To discuss the mechanisms of plaque disruption and the role of thrombosis.

Main Methods:

  • Review of current literature on atherosclerosis and ACS.
  • Classification of atherosclerotic lesions.

Related Experiment Videos

  • Analysis of plaque vulnerability, thrombosis mechanisms, and lipid-modifying strategies.

    • Main Results:

    • Type IV and Va lesions are small but vulnerable due to high lipid content, leading to "passive" plaque disruption.
    • Macrophage activity contributes to an "active" plaque disruption via the tissue factor pathway.
    • Therapeutic reduction of LDL-cholesterol promotes cholesterol efflux, decreasing plaque softness.
    • Experimental increase in HDL-cholesterol reduces macrophage number and activity, mitigating "active" disruption.

    Conclusions:

    • Lipid-modifying strategies are crucial for stabilizing vulnerable plaques.
    • Reducing LDL-cholesterol and increasing HDL-cholesterol offer dual benefits in preventing ACS.
    • Understanding plaque biology and thrombosis is key to effective secondary prevention.